The Journal of Aerosol Medicine and Pulmonary Drug Delivery, published by MARY ANN LIEBERT, INC, is a distinguished journal dedicated to advancing the field of aerosol medicine and pharmacology. With an ISSN of 1941-2711 and E-ISSN 1941-2703, the journal has established itself as an essential resource for researchers and professionals specializing in pharmaceutical sciences and pulmonary medicine. Ranking in the Q2 category across multiple disciplines, including Pharmaceutical Science and Pulmonary and Respiratory Medicine, it holds notable Scopus rankings, with a percentile of 78th in Pulmonary and Respiratory Medicine. The journal offers open access options, ensuring that cutting-edge research is readily available to a global audience. With converged years from 2008 to 2024, the Journal of Aerosol Medicine and Pulmonary Drug Delivery continues to serve as a vital platform for disseminating innovative research findings, clinical practice insights, and technological advancements in drug delivery systems, thereby significantly impacting therapeutic strategies for respiratory diseases.

Asian Journal of Pharmaceutical Research and Health Care, published by Wolters Kluwer Medknow Publications, serves as a vital platform for disseminating cutting-edge research in the fields of pharmacology, toxicology, and healthcare. With an ISSN of 2250-1444 and an E-ISSN of 2250-1460, this journal aims to provide valuable insights and advancements in pharmaceutical sciences, targeting researchers, practitioners, and students dedicated to improving health outcomes. Although its coverage in Scopus was discontinued in 2016, the journal maintains importance within the academic community by fostering discourse and sharing knowledge on emerging topics. Despite its challenges reflected in the low Scopus ranking within its category, the Asian Journal of Pharmaceutical Research and Health Care remains committed to enhancing access to critical research and publishing high-quality work that bridges the gap between theory and practice in health care. Researchers and professionals engaged in the pharmaceutical field are encouraged to contribute and leverage this journal as a means to advance their work and elevate healthcare standards in Asia and beyond.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

The Journal of Pharmaceutical Innovation, published by SPRINGER, serves as a vital resource in the fields of Pharmaceutical Science and Drug Discovery. With an ISSN of 1872-5120 and an E-ISSN of 1939-8042, this journal has been disseminating significant research findings since its inception in 2006. It is recognized for its rigorous peer-review process, maintaining a respectable ranking of Q2 in Pharmaceutical Science and Q3 in Drug Discovery as of 2023. Researchers and practitioners benefit from the journal's diverse scope, which encompasses innovative methodologies and advancements in pharmaceuticals, thereby fostering knowledge and collaboration within the scientific community. Although it does not offer Open Access options, the journal is accessible through institutional subscriptions and libraries, ensuring that critical insights in drug development and pharmacology reach a broad audience. The geographical presence of the journal in the United States underscores its influence in shaping the pharmaceutical landscape on a global scale.

Journal of Pharmaceutical Investigation, published by SPRINGERNATURE, is a leading academic resource in the field of pharmaceutical sciences, offering critical insights and innovative research findings. With an impact factor that underscores its significance, this journal ranks in the Q1 category for both Pharmacology and Pharmaceutical Science as of 2023, showcasing its high-quality publications and rigorous peer-review processes. Operating from the Netherlands, the journal spans from 2012 to 2024, offering a rich archive of interdisciplinary research contributions that advance knowledge in pharmacology, toxicology, and pharmaceutics. It holds impressive Scopus rankings, placing it among the top-tier journals in its categories, which enhances its appeal to researchers, professionals, and students aiming to publish their work or stay up-to-date with the latest advancements in the pharmaceutical field. Engaging with the Journal of Pharmaceutical Investigation not only enriches your understanding but also connects you with a community dedicated to advancing healthcare and therapeutic innovations.

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.

The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

Pharmaceutics is a prestigious journal published by MDPI, specializing in the field of pharmaceutical sciences. With its Open Access model established in 2010, it promotes the dissemination of cutting-edge research, catering to a global audience of researchers, professionals, and students alike. Based in Switzerland, the journal has rapidly gained recognition, currently holding an impressive Q1 ranking in the pharmaceutical science category for 2023 and achieving a Scopus ranking of #32 out of 183 in the domain of Pharmacology, Toxicology, and Pharmaceutics, placing it in the 82nd percentile. The journal's objectives include advancing knowledge in drug formulation, delivery systems, and therapeutic applications, ensuring that published works contribute significantly to both academic discourse and practical applications in the pharmaceutical industry. As part of its commitment to excellence, Pharmaceutics welcomes high-quality manuscripts that inspire innovation and foster collaboration in this vital field.